Skip to content
AnalystLens

Leidos Holdings 8-K Report, Financial Results (Feb 11, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 11, 2025
Period End
February 11, 2025
Security
LDOS
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed February 11, 2025. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. reported financial results for its fourth quarter and fiscal year ended January 3, 2025, as furnished in Exhibit 99.1 (press release dated February 11, 2025).

Fourth-quarter revenues were $4.37 billiona, up 10% year-over-year, and net income was $282 million, or $2.12 per diluted share. For the full year, revenues were $16.66 billion, up 8%, and net income was $1,251 million, or $9.22 per diluted share, compared with $208 million, or $1.44 per diluted share, in fiscal 2023, which included goodwill and asset impairment and restructuring charges tied to the Security Enterprise Solutions reporting unit. Non-GAAP diluted EPS was $2.37 for the quarter (up 19%) and $10.21 for the year (up 40%).

Adjusted EBITDA for the year was $2.15 billionb, a 12.9% margin. Cash flow and backlog were strong. Net cash provided by operating activities was $299 million in the quarter and $1.39 billion for the year, with free cash flow of $1.24 billion for the year.

The company returned $459 millionc to shareholders in the quarter, including $406 million in share repurchases. Net bookings were $23.4 billion for fiscal 2024, a book-to-bill ratio of 1.4, and backlog ended the year at $43.6 billion. Cash and cash equivalents were $943 million and debt was $4.7 billion at year-end.

For fiscal 2025, Leidos guided to revenues of $16.9 to $17.3 billiond, an adjusted EBITDA margin in the mid-to-high 12% range, non-GAAP diluted EPS of $10.35 to $10.75, and operating cash flow of approximately $1.45 billion. The Board also declared a quarterly cash dividend of $0.40 per share, payable March 28, 2025, to holders of record on March 14, 2025.

Key Highlights

  1. Q4 FY2024 revenue of $4.37 billion, up 10% year-over-year, with growth driven by strong demand across all customer segments, especially managed health services.
  2. Full-year FY2024 diluted EPS of $9.22 versus $1.44 in FY2023, and non-GAAP diluted EPS of $10.21, up 40%; the prior year included impairment and restructuring charges tied to the SES reporting unit.
  3. Health & Civil segment operating margin reached 21.8% for the year, compared with 13.5% in the prior year, driven by higher managed health services volumes and case complexity.
  4. Fiscal 2024 net bookings of $23.4 billion (book-to-bill 1.4) brought backlog to $43.6 billion, of which $8.4 billion was funded.
  5. Full-year free cash flow of $1.24 billion; the company returned $459 million to shareholders in Q4, including $406 million in share repurchases.
  6. FY2025 guidance calls for revenues of $16.9 to $17.3 billion and non-GAAP diluted EPS of $10.35 to $10.75, with operating cash flow of approximately $1.45 billion.
  7. Notable awards included a five-year, $4.1 billion IDIQ for the IFPC Increment 2 Program and a TSA checkpoint sustainment contract with a maximum value of $2.6 billion.

Frequently Asked Questions

  1. How did Leidos perform in the fourth quarter and full fiscal year 2024?

    Q4 revenue was $4.37 billion, up 10%, and diluted EPS was $2.12, up 28%. For the full year, revenue was $16.66 billion, up 8%, and diluted EPS was $9.22, compared with $1.44 in fiscal 2023, which included impairment and restructuring charges.

  2. What is Leidos guiding for fiscal 2025?

    Leidos guided to revenues of $16.9 to $17.3 billion, an adjusted EBITDA margin in the mid-to-high 12% range, non-GAAP diluted EPS of $10.35 to $10.75, and cash flows from operating activities of approximately $1.45 billion.

  3. How strong is the company's backlog and order book?

    Net bookings were $7.6 billion in the fourth quarter and $23.4 billion for fiscal 2024, with book-to-bill ratios of 1.7 and 1.4. Backlog at year-end was $43.6 billion, of which $8.4 billion was funded.

  4. How much cash is Leidos returning to shareholders?

    In the fourth quarter, Leidos returned $459 million to shareholders, including $406 million in share repurchases and $53 million in regular quarterly dividends. The Board declared a $0.40 per share dividend payable March 28, 2025.

  5. What drove the improvement in segment profitability?

    The Health & Civil segment's operating margin rose to 21.8% for the year from 13.5%, driven by higher managed health services volumes, case complexity, and net write-ups on certain programs. Commercial & International's margin was held down by the rebaselining of certain UK contracts in the second quarter of 2024.